<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2358">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730427</url>
  </required_header>
  <id_info>
    <org_study_id>GX-I7-COV-009</org_study_id>
    <nct_id>NCT04730427</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19</brief_title>
  <official_title>A Phase 1b Study to Investigate the Safety and Preliminary Efficacy of GX-I7 in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 1b clinical trial to investigate the safety and preliminary effects of&#xD;
      a single dose of a test drug or placebo to the subjects who has diagnosed as COVID-19&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 1b clinical trial to investigate the safety and preliminary effects of&#xD;
      a single dose of a test drug or placebo to the subjects who has diagnosed as COVID-19&#xD;
      infection.&#xD;
&#xD;
      Study design: prospective, randomized, placebo-controlled, single-blind, single-center&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate, characteristics, and severity of adverse reactions</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the safety of GX-I7 in patients with COVID-19 (rating according to NCI CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift from baseline of vital sign</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>The number of patients in vital sign shifted from normal or abnormal (NCS) to abnormal (CS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift from baseline of physical examination</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>The number of patients in physical examination shifted from normal or abnormal (NCS) to abnormal (CS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift from baseline of hematology</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>The number of patients in hematology shifted from normal or abnormal (NCS) to abnormal (CS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shift from baseline of blood chemistry</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>The number of patients in blood chemistry shifted from normal or abnormal (NCS) to abnormal (CS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>The incident rate of DLT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute lymphocyte count (ALC)</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>The change of absolute lymphocyte count from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RT-PCR for COVID-19</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the efficacy of GX-I7 in patients with COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical improvement by modified early warning score (MEWS)</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Changes of modified early warning score (MEWS) from the baseline after the IP administration [Low-risk (score 0) ~ high-risk (score 3)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal scale for clinical improvement (WHO) in each visit</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Changes of ordinal scale for clinical improvement (WHO) from the baseline after the IP administration [Uninfected 0 ~ Dead 8]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who have progressed to death or a critical illness</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the efficacy of GX-I7 in patients with COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune repertoire</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Changes in the rate of different immune cell types and regulatory T cell in the blood after the IP administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>GX-I7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-I7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GX-I7 vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GX-I7 vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-I7</intervention_name>
    <description>Recombinant human interleukin-7 hybrid Fc</description>
    <arm_group_label>GX-I7</arm_group_label>
    <other_name>Efineptakin alfa</other_name>
    <other_name>rhIL-7-hyFc</other_name>
    <other_name>NT-I7</other_name>
    <other_name>TJ107</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-I7 vehicle</intervention_name>
    <description>Formulation buffer of recombinant human interleukin-7 hybrid Fc</description>
    <arm_group_label>GX-I7 vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who have been confirmed to be COVID-19 corresponding to mild cases of&#xD;
             severity categorization classified by FDA through polymerase chain reaction (PCR) test&#xD;
             or virus gene test (sequencing) and who can be available to be administered within&#xD;
             seven days from the date of manifestation.&#xD;
&#xD;
          2. Subjects who are or will be inpatient.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Patients with symptoms of moderate or higher in the severity classification presented&#xD;
             by FDA have evidence of lower respiratory tract infection in their imaging findings or&#xD;
             need supplemental oxygen therapy or mechanical respiration (ie, non-invasive&#xD;
             ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation,&#xD;
             etc)&#xD;
&#xD;
          2. Subjects with infectious diseases such as bacteremia or severe pneumonia requiring&#xD;
             active treatment within four weeks prior to the IP administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minkyu Heo</last_name>
    <role>Study Director</role>
    <affiliation>Genexine_Clinical Development Dept.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minkyu Heo</last_name>
    <phone>+82-31-628-3340</phone>
    <email>mkheo@genexine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Borame Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DEOG KYEOM KIM, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

